VATS for Pleural Mesothelioma: 3 Thoracoscopic Procedures

Video-assisted thoracoscopic surgery is one of the first procedures many mesothelioma patients encounter, often before they even have a confirmed diagnosis. In malignant pleural mesothelioma, VATS and the closely related medical thoracoscopy are used to look directly at the diseased pleural lining, take biopsies, and manage the fluid buildup that makes breathing difficult. Understanding what these minimally invasive procedures can — and cannot — do helps patients and families make informed decisions alongside their care team.

What are VATS and thoracoscopic procedures in pleural mesothelioma?

VATS stands for video-assisted thoracoscopic surgery. A surgeon makes one to three small incisions in the chest wall and inserts a thoracoscope — a thin tube with a camera — along with specialized instruments. The camera projects a magnified view of the pleural space onto a monitor, allowing the surgeon to operate without opening the chest. Medical thoracoscopy, also called pleuroscopy, is a closely related technique often performed by pulmonologists under local anesthesia and sedation.

In mesothelioma, these thoracoscopic approaches serve three main purposes: establishing the diagnosis, draining and controlling pleural effusion, and occasionally removing visible tumor from the pleural surface. They are minimally invasive procedures focused on diagnosis and symptom control. They are different from the major operations — pleurectomy/decortication and extrapleural pneumonectomy — that aim to remove as much tumor as possible as part of aggressive multimodal therapy.

To understand how the disease itself behaves and why the pleural lining is involved, our overview of pleural mesothelioma explains the anatomy and progression in plain language.

How does thoracoscopy diagnose mesothelioma?

Diagnosis is where thoracoscopy delivers its greatest value. Mesothelioma is notoriously difficult to confirm because its cells can resemble other cancers and benign conditions under the microscope. Pathologists need a generous tissue sample to run the panel of immunohistochemistry stains — markers such as calretinin, WT-1, and D2-40 — that distinguish mesothelioma from lung cancer and reactive tissue.

Medical thoracoscopy is widely regarded as the method of choice for investigating an undiagnosed exudative pleural effusion [1]. Because the operator can see the pleural surface directly and target abnormal areas, thoracoscopic biopsy captures larger, more representative samples than blind needle techniques. A review of pleural biopsy methods found that thoracoscopic and image-guided biopsies have a far higher diagnostic yield than older blind pleural biopsy, and that cutting-needle biopsies outperform fine-needle aspiration for malignancy — especially mesothelioma [2].

"For so many of the families I work with, the thoracoscopy is the moment the uncertainty ends. A direct-vision biopsy gives the pathologist enough tissue to say definitively whether this is mesothelioma — and that answer drives everything that comes next, from treatment to a compensation claim."

— David Foster, Executive Director of Patient Support & Medical Assistance, Danziger & De Llano

For a deeper look at how the diagnostic tissue is obtained and interpreted, our reference on mesothelioma biopsy procedures walks through each step.

What is talc pleurodesis and how does it control pleural effusion?

Most pleural mesothelioma patients develop a pleural effusion — fluid that collects between the lung and chest wall and causes shortness of breath. Draining the fluid relieves symptoms temporarily, but it usually returns. Talc pleurodesis is the standard procedure for stopping that recurrence.

During thoracoscopy, the surgeon distributes sterile talc powder across the pleural surface. The talc triggers a controlled inflammatory reaction that fuses the two layers of the pleura together, eliminating the space where fluid would otherwise accumulate. When performed during thoracoscopy under direct vision, this is sometimes called talc poudrage. Pleurodesis is one of the most common and effective palliative procedures in mesothelioma care, and it can dramatically improve a patient's breathing and quality of life.

What did the MesoVATS trial show about VAT pleurectomy?

For years, surgeons debated whether a more aggressive thoracoscopic operation — video-assisted thoracoscopic partial pleurectomy (VAT-PP), in which visible tumor and the affected pleura are physically removed — could control fluid better and extend survival compared with simple talc pleurodesis. The MesoVATS trial was designed to answer that question.

Published in The Lancet in 2014, MesoVATS randomly assigned 196 patients with confirmed or suspected mesothelioma and pleural effusion to either VAT-PP or talc pleurodesis across 12 UK hospitals [3]. Among the 175 patients with confirmed mesothelioma, one-year overall survival was 52% with VAT-PP versus 57% with talc pleurodesis — a difference that was not statistically significant (hazard ratio 1.04, 95% CI 0.76–1.42; p=0.81).

The trade-offs ran against surgery. Surgical complications were significantly more common after VAT-PP, occurring in 31% of patients versus 14% after talc pleurodesis (p=0.019). Median hospital stay was more than twice as long: 7 days for VAT-PP compared with 3 days for talc pleurodesis (p<0.0001). The authors concluded that VAT-PP is not recommended to improve survival, and that talc pleurodesis may be preferable given the fewer complications and shorter recovery [3].

"MesoVATS was an important result for patients to know about. More surgery is not automatically more benefit. When a randomized trial shows the gentler option delivers the same survival with fewer complications and half the hospital time, that is information families deserve to have when they sit down with their surgical team."

— David Foster, Executive Director of Patient Support & Medical Assistance, Danziger & De Llano

How does VATS compare to major surgical resection?

It is important not to confuse the thoracoscopic procedures described here with the major cytoreductive operations used in selected, fitter patients. Extended pleurectomy/decortication and extrapleural pneumonectomy are extensive surgeries that aim to remove all visible disease, usually as part of multimodal therapy combined with chemotherapy and sometimes radiation.

The evidence for aggressive surgery has also grown more cautious. The MARS2 trial, published in 2024, found that adding extended pleurectomy/decortication to chemotherapy did not improve overall survival compared with chemotherapy alone, and was associated with more serious adverse events [4]. Together, MesoVATS and MARS2 point in the same direction: surgical benefit in mesothelioma is confined to carefully selected patients, and minimally invasive thoracoscopy remains most valuable for diagnosis and palliation. Patients weighing these options should review the full National Cancer Institute treatment summary with their care team.

What are the risks of thoracoscopic procedures in mesothelioma?

Thoracoscopic procedures are generally safe and far less invasive than open chest surgery, but they are not risk-free. Reported complications include surgical and respiratory problems, prolonged air leak from the lung, bleeding, infection, and post-procedure pain. MesoVATS documented these complications more often after partial pleurectomy than after talc pleurodesis [3].

One risk is specific to mesothelioma: tract seeding, in which tumor cells grow along the path of a biopsy needle, drainage tube, or surgical port in the chest wall. Researchers have observed that smaller biopsy ports — like those used for image-guided biopsy — may reduce the rate of tract invasion [2]. Patients should discuss this risk, and any measures to reduce it, with their thoracic surgeon. Because procedure choice depends on lung function, disease stage, and overall fitness, these decisions are best made at an experienced mesothelioma center.

Why does an accurate thoracoscopic diagnosis matter for compensation?

Beyond treatment, the tissue obtained during thoracoscopy has a second purpose that patients and families should not overlook. A tissue-confirmed mesothelioma diagnosis — with the pathology report documenting the mesothelial markers — is the medical foundation of every asbestos compensation claim. Asbestos trust funds, VA benefits, and lawsuits all require proof of diagnosis, and the operative note and pathology report from a thoracoscopic biopsy provide exactly that documentation.

Because mesothelioma is almost always caused by asbestos exposure that occurred decades earlier, building a claim also means reconstructing where and when that exposure happened. An experienced attorney can pair the medical record with an exposure history to identify the responsible companies. If you or a loved one has been diagnosed, you can connect with mesothelioma attorneys, learn how asbestos trust fund claims work, and — for former service members — review veterans benefits for asbestos-related disease. You can also take a free, confidential case assessment quiz to understand your options.

The bottom line for patients and families

VATS and thoracoscopic procedures are among the most useful tools in pleural mesothelioma — but their value lies primarily in delivering a definitive diagnosis and relieving the breathlessness caused by pleural fluid. The randomized evidence is clear that adding a thoracoscopic partial pleurectomy does not extend survival over the simpler talc pleurodesis, and that more aggressive surgery belongs only to carefully selected patients. For most people, the gentlest effective procedure is also the wisest. And whatever the treatment path, the tissue diagnosis these procedures provide is what unlocks both the right care and the compensation that asbestos victims are owed.

The team at Danziger & De Llano has helped mesothelioma patients and their families pursue justice for decades. To talk through your diagnosis and your legal options, call (855) 699-5441 or tap here to call for a free, confidential consultation. Additional patient and treatment resources are available through Mesothelioma.net.